---
document_datetime: 2023-09-21 17:10:44
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/regranex-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: regranex-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 0.6853618
conversion_datetime: 2025-12-30 22:20:40.788376
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## I BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Janssen-Cilag  International  N.V.  submitted  on  22  October  1997  an  application  for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA), in  accordance  with  the  Centralised  Procedure  falling  within  the  scope  of  Part  A  of  the  Annex  to Council Regulation No (EC) 2309/93 of 22 July 1993, as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were:

Rapporteur:

Dr. D. Jefferys

Co-Rapporteur:   Prof. J-H. Trouvin

- The applicant submitted on 2 December 1998 responses to the outstanding issues which were identified in the list of outstanding issues adopted during the CPMP meeting of 17-19 November 1998.

Licensing status Regranex has been given a marketing authorisation in the following countries: USA 16 December 1997 Israel 29 October 1998 Mexico 29 October 1998 Singapore 9 December 1998 Brazil 21 December 1998 Canada 30 December 1998 Argentina 30 December 1998 A new drug application was filed in the following countries: South Africa, South Korea, Australia, Switzerland, Russia, Thailand, New Zealand and PR China. 2. Steps taken for the assessment of the product · The procedure started on 21 November 1997. · During its meeting on 16-17 December 1997, the CPMP decided that a GMP inspection of the manufacturing facilities for the active ingredient and packaging is necessary. · The Rapporteur's first assessment report was circulated to all CPMP Members on 4 February 1998. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 2 February 1998. · During  its  meeting  on  23-26  March  1998,  the  CPMP  agreed  on  the  consolidated  list  of questions  to  be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the company on 26 March 1998. · On 27 May 1998 a meeting took place between Rapporteur, Co-Rapporteur and Company. · The company submitted the responses to the consolidated list of questions on 25 August 1998. · The Rapporteur and the Co-Rapporteur circulated the joint response assessment report on the company's responses to the list of questions to all CPMP Members on 26 October 1998. · During its meeting on 17-19 November 1998, the CPMP agreed on a list of outstanding issues (pharmaceutical and clinical aspects) to be addressed by the company in an oral explanation. The  clock  was  stopped  in  order  to  allow  the  applicant  to  prepare  for  the  oral  explanation scheduled during the December CPMP meeting. Medicinal product no longer authorised

- An assessment of the response to the outstanding issues, clinical aspects was circulated to the CPMP members on 10 December 1998.
- An assessment of the response to the outstanding issues, pharmaceutical aspects was circulated to the CPMP members on 10 December 1998.

<div style=\"page-break-after: always\"></div>

- An  oral  presentation  was  held  at  the  CPMP  meeting  on  16  December  1998,  to  address  the remaining outstanding issues.
- The CPMP, during their meeting on 15-17 December 1998, considered the responses provided by the company and discussed the recommendations presented by the Rapporteur. Amendments were discussed to the Summary of Product Characteristics and Package Leaflet texts.
- The  applicant  (Janssen-Cilag  International  N.V.)  provided  a  letter  of  undertaking  on  the commitments to be fulfilled as requested by the CPMP, dated 16 December 1998.
- During  the  meeting  on  15-17  December  1998  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation for Regranex on 17 December 1998 .
- The  CPMP  opinion  was  forwarded,  in  all  official  languages  of  the  European  Union,  to  the European Commission which adopted the corresponding Decisions on 29 March 1999. Medicinal product no longer authorised